Jung Sun Kim

Dr. Jung Sun Kim

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2015 in JAMA
Verified
Journal Article
Open access
PDF file
SHSung-Jin Hong
Sung-Jin Hong
BKByeong‐Keuk Kim
Byeong‐Keuk Kim
DSDong-Ho Shin
Dong-Ho Shin
CNChung Mo Nam
Chung Mo Nam
Jung Sun KimJung Sun Kim
Jung Sun Kim
FIfor the IVUS-XPL Investigators
for the IVUS-XPL Investigators
The introduction of the drug-eluting stent (DES) has contributed to a significant reduction in in-stent restenosis and repeat revascularization.1,2 However, despite the use of the DES, percutaneous coronary intervention (PCI) of diffuse long coronary lesions still remains challenging because the prevalence of in-stent restenosis and stent thrombosis remains high compared with short-length coronary lesions.3,4

1 October 2012 in JACC
Verified
Journal Article
Closed access
BKByeong‐Keuk Kim
Byeong‐Keuk Kim
MHMyeong-Ki Hong
Myeong-Ki Hong
DSDong-Ho Shin
Dong-Ho Shin
CNChung Mo Nam
Chung Mo Nam
Jung Sun KimJung Sun Kim
Jung Sun Kim
YJYangsoo Jang
Yangsoo Jang

1 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SKSo Ra Kim
So Ra Kim
SLSang-Guk Lee
Sang-Guk Lee
SKSoo Hyun Kim
Soo Hyun Kim
JKJin Hee Kim
Jin Hee Kim
ECEunhye Choi
Eunhye Choi
YLYong-ho Lee
Yong-ho Lee
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events in humans with type 2 diabetes (T2D); however, the underlying mechanism remains unclear. Activation of the NLR family, pyrin domain-containing 3 (NLRP3) inflammasome and subsequent interleukin (IL)-1β release induces atherosclerosis and heart failure. Here we show the effect of SGLT2 inhibitor empagliflozin on NLRP3 inflammasome activity. Patients with T2D and high cardiovascular risk receive SGLT2 inhibitor or sulfonylurea for 30 days, with NLRP3 inflammasome activation analyzed in macrophages. While the SGLT2 inhibitor’s glucose-lowering capacity is similar to sulfonylurea, it shows a greater reduction in IL-1β secretion compared to sulfonylurea accompanied by increased serum β-hydroxybutyrate (BHB) and decreased serum insulin. Ex vivo experiments with macrophages verify the inhibitory effects of high BHB and low insulin levels on NLRP3 inflammasome activation. In conclusion, SGLT2 inhibitor attenuates NLRP3 inflammasome activation, which might help to explain its cardioprotective effects.

1 July 2015 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
BKByeong‐Keuk Kim
Byeong‐Keuk Kim
DSDong-Ho Shin
Dong-Ho Shin
MHMyeong-Ki Hong
Myeong-Ki Hong
HPHun Sik Park
Hun Sik Park
SRSeung-Woon Rha
Seung-Woon Rha
YJYangsoo Jang
Yangsoo Jang
Background—: There have been no randomized studies comparing intravascular ultrasound (IVUS)–guided versus conventional angiography–guided chronic total occlusion (CTO) intervention using new-generation drug-eluting stent Therefore, we conducted a prospective, randomized, multicenter trial designed to test the hypothesis that IVUS-guided CTO intervention is superior to angiography-guided intervention. Methods and Results—: After successful guidewire crossing, 402 patients with CTOs were randomized to the IVUS-guided group (n=201) or the angiography-guided group (n=201) and secondarily randomized to Resolute zotarolimus-eluting stents or Nobori biolimus-eluting stents. The primary and secondary end points were cardiac death and a major adverse cardiac event defined as the composite of cardiac death, myocardial infarction, or target-vessel revascularization, respectively. After 12-month follow-up, the rate of cardiac death was not significantly different between the IVUS-guided group (0%) and the angiography-guided group (1.0%; P by log-rank test=0.16). However, major adverse cardiac event rates were significantly lower in the IVUS-guided group than that in the angiography-guided group (2.6% versus 7.1%; P =0.035; hazard ratio, 0.35; 95% confidence interval, 0.13–0.97). Occurrence of the composite of cardiac death or myocardial infarction was significantly lower in the IVUS-guided group (0%) than in the angiography-guided group (2.0%; P =0.045). The rates of target-vessel revascularization were not significantly different between the 2 groups. In the comparison between Resolute zotarolimus-eluting stent and Nobori biolimus-eluting stent, major adverse cardiac event rates were not significantly different (4.0% versus 5.7%; P =0.45). Conclusions—: Although IVUS-guided CTO intervention did not significantly reduce cardiac mortality, this randomized study demonstrated that IVUS-guided CTO intervention might improve 12-month major adverse cardiac event rate after new-generation drug-eluting stent implantation when compared with conventional angiography-guided CTO intervention. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01563952.

1 January 2020 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
SHSung-Jin Hong
Sung-Jin Hong
GMGary S. Mintz
Gary S. Mintz
CAChul-Min Ahn
Chul-Min Ahn
Jung Sun KimJung Sun Kim
Jung Sun Kim
BKByeong‐Keuk Kim
Byeong‐Keuk Kim
MHMyeong-Ki Hong
Myeong-Ki Hong

15 November 2018 in Molecules
Verified
Journal Article
Open access
PDF file
PSPrabhakaran Soundararajan
Prabhakaran Soundararajan
Jung Sun KimJung Sun Kim
Jung Sun Kim
Glucosinolates (GSL) are naturally occurring β-d-thioglucosides found across the cruciferous vegetables. Core structure formation and side-chain modifications lead to the synthesis of more than 200 types of GSLs in Brassicaceae. Isothiocyanates (ITCs) are chemoprotectives produced as the hydrolyzed product of GSLs by enzyme myrosinase. Benzyl isothiocyanate (BITC), phenethyl isothiocyanate (PEITC) and sulforaphane ([1-isothioyanato-4-(methyl-sulfinyl) butane], SFN) are potential ITCs with efficient therapeutic properties. Beneficial role of BITC, PEITC and SFN was widely studied against various cancers such as breast, brain, blood, bone, colon, gastric, liver, lung, oral, pancreatic, prostate and so forth. Nuclear factor-erythroid 2-related factor-2 (Nrf2) is a key transcription factor limits the tumor progression. Induction of ARE (antioxidant responsive element) and ROS (reactive oxygen species) mediated pathway by Nrf2 controls the activity of nuclear factor-kappaB (NF-κB). NF-κB has a double edged role in the immune system. NF-κB induced during inflammatory is essential for an acute immune process. Meanwhile, hyper activation of NF-κB transcription factors was witnessed in the tumor cells. Antagonistic activity of BITC, PEITC and SFN against cancer was related with the direct/indirect interaction with Nrf2 and NF-κB protein. All three ITCs able to disrupts Nrf2-Keap1 complex and translocate Nrf2 into the nucleus. BITC have the affinity to inhibit the NF-κB than SFN due to the presence of additional benzyl structure. This review will give the overview on chemo preventive of ITCs against several types of cancer cell lines. We have also discussed the molecular interaction(s) of the antagonistic effect of BITC, PEITC and SFN with Nrf2 and NF-κB to prevent cancer.